



Published in final edited form as:

Childs Nerv Syst. 2012 April ; 28(4): 521–532. doi:10.1007/s00381-012-1704-1.

Matching mice to malignancy: molecular subgroups and models of medulloblastoma

Jasmine Lau,

Department of Neurology, University of California, San Francisco, CA, USA. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA. Department of Neurological Surgery and Brain Tumor Research Center, University of California, San Francisco, CA, USA. Department of Pediatrics, University of California, San Francisco, CA, USA

Christin Schmidt,

Department of Neurology, University of California, San Francisco, CA, USA. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA. Department of Neurological Surgery and Brain Tumor Research Center, University of California, San Francisco, CA, USA. Department of Pediatrics, University of California, San Francisco, CA, USA

Shirley L. Markant,

Tumor Development Program, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA. Department of Pharmacology & Cancer Biology, Duke University Medical Center, Durham, NC, USA

Michael D. Taylor,

Division of Neurosurgery, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. Arthur and Sonia Labatt Brain Tumour Research Centre, Program in Developmental and Stem Cell Biology, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

Robert J. Wechsler-Reya, and

Tumor Development Program, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA. Department of Pharmacology & Cancer Biology, Duke University Medical Center, Durham, NC, USA

William A. Weiss

Department of Neurology, University of California, San Francisco, CA, USA. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA. Department of Neurological Surgery and Brain Tumor Research Center, University of California, San Francisco, CA, USA. Department of Pediatrics, University of California, San Francisco, CA, USA

William A. Weiss: wweiss@ucsf.edu

Abstract

Introduction—Medulloblastoma, the largest group of embryonal brain tumors, has historically been classified into five variants based on histopathology. More recently, epigenetic and transcriptional analyses of primary tumors have sub-classified medulloblastoma into four to six subgroups, most of which are incongruous with histopathological classification.

Discussion—Improved stratification is required for prognosis and development of targeted treatment strategies, to maximize cure and minimize adverse effects. Several mouse models of medulloblastoma have contributed both to an improved understanding of progression and to

developmental therapeutics. In this review, we summarize the classification of human medulloblastoma subtypes based on histopathology and molecular features. We describe existing genetically engineered mouse models, compare these to human disease, and discuss the utility of mouse models for developmental therapeutics. Just as accurate knowledge of the correct molecular subtype of medulloblastoma is critical to the development of targeted therapy in patients, we propose that accurate modeling of each subtype of medulloblastoma in mice will be necessary for preclinical evaluation and optimization of those targeted therapies.

Keywords

Medulloblastoma; Mouse models; Molecular subgroups; Targeted therapies; Preclinical testing

Introduction

Medulloblastoma, a highly aggressive WHO-grade IV embryonal tumor of the cerebellum [1, 2], is the most common malignant brain tumor in children. Medulloblastoma accounts for 20% of pediatric central nervous system tumors [3], and the incidence is 0.6 per 100,000 children in patients 0–19 years [4–6], decreasing with age. Seventy percent of cases occur in children younger than 10 years of age [6].

Leptomeningeal dissemination occurs in 30% of cases at presentation and is the strongest predictor of poor prognosis [7, 8]. The extent of surgical resection, which is affected by involvement of the brainstem, and the degree of tumor dissemination are also highly predictive of outcome [7, 9]. Multimodal surgical resection, radiation, and chemotherapy have led to modest improvements in overall survival over the last decade. Five-year survival rates are now as high as 70–80% in standard-risk patients [10–12], but survival is often achieved at the cost of treatment-induced morbidities [13–16]. Moreover, survivors suffer the continued risk of secondary tumors, relapse, and metastasis [17]. Despite the improved outcomes for standard-risk patients, the prognosis for high-risk patients (younger than 3 years old, or significant residual post-operative tumor, or leptomeningeal dissemination at presentation) remains dismal at only 25–40% 5-year event-free survival [18, 19].

Classification of medulloblastoma

Medulloblastoma arises in the posterior fossa [20]. Medulloblastoma tumor cells can invade the cerebellar cortex and white matter and spread, via the cerebrospinal fluid, to the leptomeningeal membranes that cover the CNS as well as to the spinal cord. Medulloblastoma cells typically appear undifferentiated, reminiscent of stem or progenitor cells. The WHO separates medulloblastoma into five variants based on histopathological features: (a) classic, (b) desmo-plastic/nodular, (c) medulloblastoma with extensive nodularity, (d) large cell medulloblastoma, and (e) anaplastic medulloblastoma [21].

Biomarkers and molecular profiling

Several biomarkers with prognostic significance (some of which have been validated in clinical trials) have been identified for specific subtypes of medulloblastoma. The Sonic Hedgehog (SHH) signaling pathway, which is required for normal cerebellar development [21], was first implicated in medulloblastoma when patients with Gorlin's syndrome, who develop nevoid basal cell carcinoma [22, 23] and sporadic medulloblastoma [24–27], were found to harbor germline inactivating mutations of Patched1 (*PTCH1*). Subsequently, mutations in downstream SHH pathway components, such as Smoothed (*SMO*) and suppressor of fused (*SUFU*), and amplification of *GLI1* and *GLI2* and the miR17–92 complex were also identified in sporadic medulloblastoma [28–32]. SHH-dysregulated medulloblastomas comprise ~25% of all cases and may show desmoplastic or classic

histopathology; desmoplastic tumors in particular have been associated with better prognoses [21, 33].

The canonical WNT pathway was first implicated in medulloblastoma based on observations that a subset of patients with germline mutations in the tumor suppressor *APC* (i.e., patients with Turcot syndrome) develops medulloblastoma [34, 35]. Subsequently, 5–10% of patients with sporadic medulloblastoma were also shown to harbor activating point mutations in the β -catenin gene *CTNNB1*, resulting in aberrantly activated WNT signaling [36, 37]. Other abnormalities found in WNT tumors include promoter methylation (hence gene silencing) of the secreted frizzled-related protein 1 family of WNT inhibitors and monosomy of chromosome 6 [4, 38]. WNT-associated tumors account for ~18–25% of all cases and are usually of classic histology [37, 39].

Amplification of *MYC* genes (*c-MYC* and *MYCN*, v-myc myelocytomatosis viral-related oncogene) correlates with poor prognosis and is often found in tumors with large cell anaplastic histopathology [40]. Amplification of *c-MYC* has been reported in 5–15% of medulloblastoma overall, while amplification of *MYCN* has been found in ~10% of cases [40–42]. *TP53* loss or mutation contributes to 10–15% of cases, and Li–Fraumeni patients with germline mutations in *TP53* have increased risk of cancers, including medulloblastoma [43–45]. In addition, loss of the tumor suppressor *ARF* due to homozygous deletion or promoter hypermethylation (with wild-type *TP53*) occurs in ~10% of tumors [44]. Analysis of a small subset of human tumors has found *TP53* mutations and methylation and deletion of *ARF* in aggressive LCA tumors, demonstrating the importance of the ARF/TP53 pathway in promoting malignancy [44]. Curiously, the highest frequency of *TP53* mutations is found in WNT medulloblastomas, which have the best relative prognosis [46].

Isochromosome 17q, the most frequent chromosomal aberration in medulloblastoma, is present in 30–50% of tumors [11, 38], and together with copy number abnormalities in chromosome 17, including 17q gains, and 17p deletions, is associated with poor prognosis [40]. Two candidate tumor suppressors, hypermethylated in cancer 1 (*HIC1*), a POZ domain transcriptional repressor, and $\text{REN}^{\text{KCTD11}}$, an E3 ubiquitin ligase component that works with Cullin3 to deacetylate *GLI1* and *GLI2* [47–49], localize to this region. In medulloblastomas, *HIC1* is frequently silenced in tumors due to promoter hypermethylation [50–52], while loss of $\text{REN}^{\text{KCTD11}}$ during 17p deletion enhances SHH signaling [53].

Hypermethylation of promoters for tumor suppressor genes leads to gene silencing and may contribute to development of medulloblastoma. Implicated genes include ras association domain family protein 1, isoform A (*RASSF1A*) [54–56], serine protease inhibitor kunitz-type 2 (*SPINT2*), a tumor suppressor gene that inhibits HGF/MET signaling [57], and Kruppel-like factor 4 (*KLF4*) [58]. Finally, the NOTCH and phosphatidylinositol 3'-kinase (PI3K) signaling pathways may also contribute to medulloblastoma. Activation of the NOTCH pathway may occur as a result of overexpression or amplification of NOTCH1, NOTCH2, and downstream targets HES1 and HES5 [59, 60] or silencing of miR199b-5p, a negative regulator of NOTCH signaling [61]. The PI3K pathway has also been shown to contain aberrations in medulloblastoma; mutations in the catalytic subunit *PIK3CA* are found in ~5% of cases [62], while deletions or mutations in *PTEN* (a negative regulator of PI3K) occur in 30–35% of cases [63].

Several transcriptome analyses of human medulloblastoma samples have sub-classified this disease [38, 64–66]. Two subclasses of tumors, with dysregulated WNT or SHH signaling, have been consistently identified [38, 64–66], suggesting that these tumors arise and develop differently from other subtypes. Independent groups have classified non-WNT, non-SHH tumors into two to four subgroups; expression of neuronal and photoreceptor markers

determines the precise number of subgroups. These subgroups may be best represented as a spectrum of tumor types, with one end of the spectrum expressing a “neuronal/glutamatergic” signature, while the other end is characterized by expression of a photoreceptor/GABAergic signature. Importantly, a subset of tumors on the “photoreceptor/GABAergic” end of the spectrum also exhibits a MYC activation signature; these MYC-associated tumors are the most aggressive and display the worst prognosis.

A comparison of the broad histopathological WHO classification of classic, desmoplastic, and large cell/anaplastic tumors with the molecular/transcriptional subclasses indicates some correlation but also highlights inconsistencies in these subclassification schemes. The common classic tumors and the rare LCA tumors span all molecular subtypes, while true desmoplastic tumors are almost entirely restricted to the SHH subgroup.

Mouse models of medulloblastoma

Medulloblastoma cell lines generally lack cellular heterogeneity and components of the microenvironment, and acute transplantation of tumor cells into mice does not recapitulate the malignancy and alterations in the microenvironment that develop in situ in patients. The use of genetically engineered mouse (GEM) models provides physiologically relevant insights into human tumor settings, albeit with limitations. The first models of medulloblastoma were derived by inoculating viral agents such as adenoviruses and polyoma viruses into rodents early during postnatal cerebellar development. Among the early successes were studies using Simian adenovirus SA7 [67, 68], the JC human polyoma virus [69, 70], or the JC virus T antigen (viral early regulatory protein). Since then, GEM models of medulloblastoma have been developed using two main strategies: germline modifications via transgenes (genetic knockins or knockouts) and somatic cell gene transfer by viral transduction (Fig. 1).

SHH pathway models

Because the SHH pathway has been shown to be important in normal cerebellar development and implicated in Gorlin’s syndrome, many models have been developed to manipulate components of this pathway. These manipulations include deletion of *Ptch1*, activation of *Smo*, and deletion of *Sufu*. While homozygous deletion of *Ptch1* results in early embryonic lethality due to cardiac and neural tube defects, heterozygous mice are viable. Medulloblastoma develops in 14–19% of these mice by 10 months of age, with peak occurrence at 16–25 weeks [71–73] (systemic heterozygosity of *Ptch1* also results in other tumors, notably sarcomas). Some groups have observed the retention of wild-type *Ptch1* allele in these *Ptch1*^{+/-} tumors [71, 73], while others report loss of heterozygosity or mutation of the remaining *Ptch1* allele [74, 75]. Loss of *Ptch2* (which has 73% amino acid similarity to *Ptch1*) can cooperate with *Ptch1* heterozygosity to promote medulloblastoma progression [76], and complete loss of *p53* in *Ptch1*^{+/-} mice has also been shown to increase the incidence of tumors (95–100%) and reduce the latency to 4–16 weeks [77, 78]. Loss of *Ptch1* results in increased activity of downstream genes *Gli1* and *Cyclin D1* in cerebellar granule neuronal precursors (CGNPs) and accordingly, complete loss of *Gli1* or *Cyclin D1* in *Ptch1*^{+/-} mice results in reduced tumor incidence, demonstrating that these genes contribute significantly to SHH-driven medulloblastoma [79, 80]. In addition, *Ptch1*^{+/-} mice crossed into an *Igf2*-null background fail to develop tumors, demonstrating that IGF2 is essential for SHH-driven medulloblastoma [81, 82].

Transgenic mouse models have also been generated using activated SMO, either with the mutation W535L (*SmoM2*) in human *SMO* or the corresponding mutation W539L in mouse *Smo* (*SmoA1*). The mutation resides in the trans-membrane domain of SMO and results in SHH ligand-independent activation of downstream signaling. The *SmoM2* mouse model

uses a ubiquitously expressed *CreER* transgene to allow for tamoxifen-mediated activation of mutant *SmoM2* and induction of downstream SHH signaling [83]. Sporadic leakiness of Cre activity results in 27% of mice developing medulloblastoma, and acute activation of *SmoM2* at postnatal day 10 increases medulloblastoma incidence to 40%. The *SmoA1* mouse model uses the NeuroD2 (ND2) promoter to drive *SmoA1* expression in CGNPs [60, 84]. Hemizygous mice develop medulloblastoma at a median age of 26 weeks with 48% incidence, while 94% of homozygous mice develop tumors at 8 weeks of age.

Both the *Ptch1* and *SmoM2* models have been further engineered to restrict activated SHH signaling to cerebellar neural stem cells or CGNPs. When *hGFAP-Cre* or *Math1-Cre* drivers were used to delete *Ptch1* conditionally, tumors developed in 100% of mice by 1–3 months of age [85]. Similarly, Schüller et al. expressed activated *SmoM2* using *hGFAP*-, *Math1*-, *Olig2*-, and *Tlx3-Cre* drivers [86], where *Olig2-Cre* and *Tlx3-Cre* are specifically expressed in neuronal progenitors in the posterior EGL and remain expressed in the IGL. Medulloblastoma developed in 100% of mice using all four drivers, with an average survival of about 1–2 months. The authors also targeted *SmoM2* using the *Gli1* promoter. However, incidence of tumors was only 40%, and the animals displayed prolonged survival, suggesting that driving tumors using promoters of genes downstream from SHH less potently promotes oncogenesis [86]. Finally, a model targeting downstream *Sufu* has also been reported, in which *Sufu*^{+/-}; *p53*^{-/-} mice develop medulloblastomas with an incidence of 58% and rhabdomyosarcomas at 9% incidence by 10 months [87].

The other main strategy for generating GEM models of medulloblastoma is somatic cell gene transfer. Early studies used SHH-expressing Moloney murine leukemia viruses injected in utero into embryonic day 13.5 mouse cerebellum. Medulloblastoma arose in 76% of animals by P14–21, suggesting that direct overexpression of SHH alone is sufficient to initiate tumors [88, 89]. SHH-expressing retroviruses have also been introduced in the cerebellum of *Gli1*^{-/-} mice. Medulloblastoma still formed, indicating that *Gli1* is not critical in this model [87]. *Gli2* was shown to be expressed in the tumors, suggesting that *Gli2* may compensate for *Gli1* loss.

To enable cell-type specific infection, the RCAS/tv-a system is now commonly used [90, 91]. The avian retrovirus RCAS (replication competent ASLV long terminal repeat with splice acceptor) only infects murine cells that are engineered to express the avian RCAS receptor tumor virus-A (tv-a), which is not normally expressed in mammalian cells [91]. RCAS-SHH retroviruses injected into Nestin promoter driving tv-a (Ntv-a) mice induce medulloblastoma at 9–39% incidence within 3 months [92–96]. Several genes of the IGF2/PI3K pathways were each introduced with SHH, including (a) IGF2, (b) an activated transforming form of AKT (Akt-Myr-Δ11–60), and (c) a stabilized, non-degradable T58A mutant NMYC [94, 95]. Additionally, RCAS-SHH system was combined with RCAS-Cre; *PTEN*-floxed mice to delete *PTEN* [97]. Viruses encoding the anti-apoptotic protein BCL-2 were also combined with SHH to block cell death mechanisms without affecting cell proliferation [93]. Combinations with all genes tested showed at least a doubling in incidence of tumors. Of note, viruses encoding IGF2, activated AKT, wild-type or mutant NMYC, and BCL-2 were not able to drive medulloblastoma in the absence of SHH, and combining NMYC with GLI1, AKT, IGF2, or BCL-2 was also insufficient to drive tumor formation. Together, these experiments suggest that the pro-tumorigenic effect of SHH is not solely mediated via NMYC and that other downstream effectors of SHH cooperate with IGF2/PI3K signaling to drive tumorigenesis.

Hepatocyte growth factor (HGF) has been shown to regulate expression of c-MYC and can cooperate with c-MYC to drive cell proliferation and apoptosis [98, 99]. High levels of HGF/c-MET receptor and amplification of c-MYC in human medulloblastoma are

independently associated with LCA tumors and poor prognosis [99]. When expressed together with SHH using the RCAS/Ntv-a system, c-MYC and HGF each cooperated with SHH to increase penetrance, aggressiveness, and regional desmoplasia [92, 96]. However, it is not clear that this combination of genes mirrors cooperative expression in human tumors [38, 98, 99].

Other models with upregulated SHH signaling include deletion of cell cycle-associated genes Rb [100, 101] and cyclin-dependent kinase inhibitor Ink4c [102]; deletion of DNA repair enzymes Lig4 [103], Xrcc4 [104], KU80 [103], Brca2 [105], and Parp1 [106]; and candidate gene on chromosome 17 *Hic1* [49]. The pathology of tumors in all of these SHH-associated models is mostly classic. Only the SHH/PTEN loss and SHH + HGF RCAS/Ntv-a models show some desmoplastic pathology, a feature characteristic of many SHH-driven human medulloblastoma tumors.

Non-SHH models

A limited number of non-SHH mouse models have also been developed. A model for WNT tumors was initiated from *Bibp*-expressing cells in the lower rhombic lip/dorsal brainstem, via activated β -catenin combined with *p53* loss [107]. Classic tumors formed in 10 months, at 4% or 15% incidence dependent on partial or complete loss of p53. Tumors formed due to accumulation of Zic1-positive post-mitotic mossy-fiber neuron precursors that failed to migrate from the dorsal brainstem to form pontine gray nuclei in the ventral brainstem. The MRIs, location, and transcriptome of the murine tumors mirrored human WNT medulloblastoma, providing evidence that the WNT subclass of tumors likely originates from the lower rhombic lip/dorsal brainstem region, distinct from SHH tumors that originate from the CGNPs in the upper rhombic lip/EGL region.

In another model, the glutamate transporter (*Glt1*) promoter and a bidirectional Tet-operator were used to drive bidirectional and simultaneous expression of human *MYCN* and luciferase in the cerebellum (GTML), resulting in primarily SHH-independent tumors with classic or LCA histopathology [108]. These *MYCN*-driven tumors demonstrated recurrent genomic aberrations, suggesting that additional events cooperate with *MYCN*. Notably, a rare number of mice showed spinal metastases, consistent with leptomeningeal spread of the malignant primary brain tumor. *MYC/MYCN* amplification is correlated with poor prognosis and aggressive LCA subtype in human tumors [40], thus supporting the use of this model in pursuing investigations of high-risk patients with poor prognosis.

Current and future use of medulloblastoma models

The early implication of SHH pathway in medulloblastoma and the vast efforts of SHH tumor modeling have facilitated the preclinical testing of a number of SHH inhibitors, often using allografted tumors from variants of the *Ptch1*^{+/-} model (Table 1). Cyclopamine is a steroidal alkaloid isolated from the corn lily *Veratrum californicum* that was discovered to inhibit tissue response to SHH signaling [109, 110] and was effective in blocking growth of SHH-driven medulloblastoma cells [74, 111]. Cyclopamine acts by binding directly to SMO, inhibiting activation of downstream SHH signaling [112, 113]. Treatment of mice with subcutaneous allograft tumors (derived from *Ptch1*^{+/-}; *p53*^{+/-} murine tumors) with cyclopamine led to decreased tumor mass and decreased proliferation [74].

Improved SMO antagonists [114, 115] include the benzimidazole derivative HhAntag-691 (HhAntag) [115], the semisynthetic cyclopamine analog IPI-926 [116], and the biphenyl carboxamide compound NVP-LDE225 [117, 118]. HhAntag treatment in young mice was reported to have permanent bone growth defects (presumably due to inhibition of Indian hedgehog signaling in the developing bone), calling into question the safety of using of this

drug in young patients [119]. Although NVP-LDE225 treatment in mice showed initial success, extended analyses showed that tumors developed resistance to the drug and regrew [118].

GDC-0449 was identified from another screen of benzimidazole derivatives that inhibits SMO at a higher efficacy than cyclopamine. Treatment of allograft models of *Ptch1*^{+/-} tumor cells at doses of 12.5 to 100 mg/kg resulted in regression [114, 120]. Nominal success was reported when a medulloblastoma patient with metastatic disease, harboring an inactivating mutation of *Ptch1*, was treated with GDC-0449. Treatment initially led to tumor regression [120], but tumors recurred, and biopsy analysis revealed a missense mutation in *Smo* resulting in an amino acid change (D473H) that disrupted drug binding to SMO and induced tumor cell resistance to GDC-0449 treatment [121]. This study highlights the need to identify agents or strategies that reduce emergence of resistant mutations. Further screens of inhibitors have since identified bis-amide compound 5 that could inhibit tumor growth of this resistant tumor strain [122]. First results from phase I clinical trials tested in patients with refractory, locally advanced, or metastatic solid tumors have reported acceptable safety profiles. Notably, of the 68 patients treated, 19 of 33 patients with basal cell carcinoma (a disease often displaying upregulated SHH pathway) showed partial or complete response [123].

In addition to SMO antagonists, other compounds have shown efficacy in causing tumor regression of SHH tumors in mice. Arsenic trioxide was found to be a GLI inhibitor [124]. The systemic antifungal, itraconazole, was found to be a SMO inhibitor [125]. The glucocorticoid dexamethasone was found to activate GSK-3 β and thereby downregulate *N-myc*, which is an important effector downstream of SHH signaling [126]. Additionally, agents targeting epigenetic regulation also have efficacy in murine medulloblastoma, including the DNA methylating agent 5-azaC [74], and histone deacetylase inhibitors suberoylanilide hydroxamic acid [127] and valproic acid [128]. Lastly, other classes of compounds not targeting the SHH pathway have been reported to be effective in treating SHH-associated tumors. In a model driven by *Ptch1* and *p53* mutations, IGF signaling was found to be upregulated, and accordingly, picropodophyllin, an inhibitor of IGF1R tyrosine phosphorylation, effectively inhibited proliferation of tumor cells isolated from the murine tumors [129]. In the *SmoA1* mouse model, tumors were found to concurrently upregulate the NOTCH pathway along with the SHH pathway. Inhibition of NOTCH signaling using soluble Delta ligand or gamma-secretase inhibitors could decrease proliferation and induce apoptosis in vitro, suggesting that SHH tumors that exhibit concurrent NOTCH activation may be effectively treated by targeting the NOTCH pathway [60]. Lastly, in the RCAS/tv-a SHH + HGF model, HGF neutralizing antibody L2G7 was more effective than SHH antagonists in increasing median survival time, suggesting potential use of HGF-targeted therapy for patients with elevated HGF levels [92, 130].

Conclusion

The development and use of relevant mouse models that closely reflect human medulloblastoma is critical to understand malignant progression in this disease and to test developmental therapeutics. Extensive progress has been made in modeling SHH tumors, with inhibitors of SHH signaling now entering clinical trials. Follow-up studies are critical to examine the mechanisms of resistance to these drugs, so that newer, more effective drugs can be developed. As WNT antagonists become available, it will be important to test the efficacy of these drugs in animal models of WNT-associated medulloblastoma. Finally, additional studies are needed to identify the drivers of non-SHH and non-WNT tumors (which comprise approximately half of all cases), so that models can be developed for these tumors as well. With robust animal models for each subtype of medulloblastoma, it should

be possible to develop appropriate targeted therapies that eradicate tumor cells while sparing patients the devastating side effects of conventional radiation and chemotherapy.

Acknowledgments

We acknowledge support from the Alex's Lemonade Stand and Pediatric Brain Tumor Foundations and from NIH grants R01CA159859, R01CA133091, R01CA148699, and R01CA122759.

References

- Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A. Medulloblastoma: from molecular pathology to therapy. *Clin Cancer Res*. 2008; 14(4):971–976.10.1158/1078-0432.CCR-07-2072 [PubMed: 18281528]
- Gilbertson RJ. Medulloblastoma: signalling a change in treatment. *Lancet Oncol*. 2004; 5(4):209–218.10.1016/S1470-2045 (04)01424-X [PubMed: 15050952]
- Saran A. Medulloblastoma: role of developmental pathways, DNA repair signaling, and other players. *Curr Mol Med*. 2009; 9(9):1046–1057. [PubMed: 19747111]
- Pfister SM, Korshunov A, Kool M, Hasselblatt M, Eberhart C, Taylor MD. Molecular diagnostics of CNS embryonal tumors. *Acta Neuropathol*. 2010; 120(5):553–566.10.1007/s00401-010-0751-5 [PubMed: 20882288]
- Momota H, Holland EC. Mouse models of CNS embryonal tumors. *Brain Tumor Pathol*. 2009; 26(2):43–50.10.1007/s10014-009-0253-0 [PubMed: 19856214]
- CBTRUS. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2006. Central Brain Tumor Registry of the United States; Hinsdale: 2010. www.cbtrus.org
- von Hoff K, Hinkes B, Gerber NU, Deinlein F, Mittler U, Urban C, Benesch M, Warmuth-Metz M, Soerensen N, Zwiener I, Goette H, Schlegel PG, Pietsch T, Kortmann RD, Kuehl J, Rutkowski S. Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. *Eur J Cancer*. 2009; 45(7):1209–1217.10.1016/j.ejca.2009.01.015 [PubMed: 19250820]
- Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, Allen JC, Stevens KR, Stanley P, Li H, Wisoff JH, Geyer JR, McGuire-Cullen P, Stehens JA, Shurin SB, Packer RJ. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 1999; 17(3): 832–845. [PubMed: 10071274]
- Albright AL, Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P. Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group. *Neurosurgery*. 1996; 38(2):265–271. [PubMed: 8869053]
- Schmidt AL, Brunetto AL, Schwartzmann G, Roesler R, Abujamra AL. Recent therapeutic advances for treating medulloblastoma: focus on new molecular targets. *CNS Neurol Disord Drug Targets*. 2010; 9(3):335–348. [PubMed: 20438440]
- Huse JT, Holland EC. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. *Brain Pathol*. 2009; 19(1):132–143.10.1111/j.1750-3639.2008.00234.x [PubMed: 19076778]
- Packer RJ, Vezina G. Management of and prognosis with medulloblastoma: therapy at a crossroads. *Arch Neurol*. 2008; 65(11):1419–1424.10.1001/archneur.65.11.1419 [PubMed: 19001159]
- Eberhart CG. Molecular diagnostics in embryonal brain tumors. *Brain Pathol*. 2011; 21(1):96–104.10.1111/j.1750-3639.2010.00455.x [PubMed: 21129063]
- Boman KK, Hovén E, Anclair M, Lannering B, Gustafsson G. Health and persistent functional late effects in adult survivors of childhood CNS tumours: a population-based cohort study. *Eur J Cancer*. 2009; 45(14):2552–2561.10.1016/j.ejca.2009.06.008 [PubMed: 19616428]
- Mulhern RK, Palmer SL, Merchant TE, Wallace D, Kocak M, Brouwers P, Krull K, Chintagumpala M, Stargatt R, Ashley DM, Tyc VL, Kun L, Boyett J, Gajjar A. Neurocognitive

- consequences of risk-adapted therapy for childhood medulloblastoma. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2005; 23(24):5511–5519.10.1200/JCO.2005.00.703 [PubMed: 16110011]
16. Frange P, Alapetite C, Gaboriaud G, Bours D, Zucker JM, Zerah M, Brisse H, Chevignard M, Mosseri V, Bouffet E, Doz F. From childhood to adulthood: long-term outcome of medulloblastoma patients. The Institut Curie experience (1980–2000). *J Neurooncol*. 2009; 95(2): 271–279.10.1007/s11060-009-9927-z [PubMed: 19521664]
 17. Oyharcabal-Bourden V, Kalifa C, Gentet JC, Frappaz D, Edan C, Chastagner P, Sariban E, Pagnier A, Babin A, Pichon F, Neuenschwander S, Vinchon M, Bours D, Mosseri V, Le Gales C, Ruchoux M, Carrie C, Doz F. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2005; 23(21):4726–4734.10.1200/JCO.2005.00.760 [PubMed: 16034048]
 18. Pizer BL, Clifford SC. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. *Br J Neurosurg*. 2009; 23(4): 364–375.10.1080/02688690903121807 [PubMed: 19637007]
 19. Taylor RE, Bailey CC, Robinson KJ, Weston CL, Walker DA, Ellison D, Ironside J, Pizer BL, Lashford LS. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. *Eur J Cancer*. 2005; 41(5):727–734.10.1016/j.ejca.2004.12.017 [PubMed: 15763649]
 20. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol*. 2007; 114(2):97–109.10.1007/s00401-007-0243-4 [PubMed: 17618441]
 21. Gilbertson RJ, Ellison DW. The origins of medulloblastoma subtypes. *Annual review of pathology*. 2008; 3:341–365.10.1146/annurev.pathmechdis.3.121806.151518
 22. Gailani MR, Bale SJ, Leffell DJ, DiGiovanna JJ, Peck GL, Poliak S, Drum MA, Pastakia B, McBride OW, Kase R. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. *Cell*. 1992; 69(1):111–117. [PubMed: 1348213]
 23. Hahn H, Wicking C, Zaphiropoulos PG, Gailani MR, Shanley S, Chidambaram A, Vorechovsky I, Holmberg E, Uden AB, Gillies S, Negus K, Smyth I, Pressman C, Leffell DJ, Gerrard B, Goldstein AM, Dean M, Toftgard R, Chenevix-Trench G, Wainwright B, Bale AE. Mutations of the human homolog of *Drosophila* patched in the nevoid basal cell carcinoma syndrome. *Cell*. 1996; 85(6):841–851. [PubMed: 8681379]
 24. Dong J, Gailani MR, Pomeroy SL, Reardon D, Bale AE. Identification of PATCHED mutations in medulloblastomas by direct sequencing. *Hum Mutat*. 2000; 16(1):89–90.10.1002/1098-1004(200007)16:1<89::AID-HUMU18>3.0.CO;2-7 [PubMed: 10874314]
 25. Vorechovský I, Tingby O, Hartman M, Strömberg B, Nister M, Collins VP, Toftgård R. Somatic mutations in the human homologue of *Drosophila* patched in primitive neuroectodermal tumours. *Oncogene*. 1997; 15(3):361–366.10.1038/sj.onc.1201340 [PubMed: 9233770]
 26. Pietsch T, Waha A, Koch A, Kraus J, Albrecht S, Tonn J, Sörensen N, Berthold F, Henk B, Schmandt N, Wolf HK, von Deimling A, Wainwright B, Chenevix-Trench G, Wiestler OD, Wicking C. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of *Drosophila* patched. *Cancer Res*. 1997; 57(11):2085–2088. [PubMed: 9187099]
 27. Raffel C, Jenkins RB, Frederick L, Hebrink D, Alderete B, Fults DW, James CD. Sporadic medulloblastomas contain PTCH mutations. *Cancer Res*. 1997; 57(5):842–845. [PubMed: 9041183]
 28. Taylor MD, Liu L, Raffel C, C-c H, Mainprize TG, Zhang X, Agatep R, Chiappa S, Gao L, Lowrance A, Hao A, Goldstein AM, Stavrou T, Scherer SW, Dura WT, Wainwright B, Squire JA, Rutka JT, Hogg D. Mutations in SUFU predispose to medulloblastoma. *Nat Genet*. 2002; 31(3): 306–310.10.1038/ng916 [PubMed: 12068298]
 29. Zurawel RH, Allen C, Chiappa S, Cato W, Biegel J, Cogen P, de Sauvage F, Raffel C. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. *Genes Chromosomes Cancer*. 2000; 27(1): 44–51. [PubMed: 10564585]
 30. Uziel T, Karginov FV, Xie S, Parker JS, Wang Y-D, Gajjar A, He L, Ellison D, Gilbertson RJ, Hannon G, Roussel MF. The miR-17 92 cluster collaborates with the Sonic Hedgehog pathway in

- medulloblastoma. *Proc Natl Acad Sci USA*. 2009; 106(8):2812–2817.10.1073/pnas.0809579106 [PubMed: 19196975]
31. Northcott PA, Fernandez-L A, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y, Grundy R, Van Meter T, Rutka JT, Croce CM, Kenney AM, Taylor MD. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. *Cancer Res*. 2009; 69(8):3249–3255.10.1158/0008-5472.CAN-08-4710 [PubMed: 19351822]
 32. Fernandez-L A, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S, Taylor MD, Kenney AM. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. *Genes Dev*. 2009; 23(23):2729–2741.10.1101/gad.1824509 [PubMed: 19952108]
 33. Ellison DW. Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. *Acta Neuropathol*. 2010; 120(3):305–316.10.1007/s00401-010-0726-6 [PubMed: 20652577]
 34. Huang H, Mahler-Araujo BM, Sankila A, Chimelli L, Yonekawa Y, Kleihues P, Ohgaki H. APC mutations in sporadic medulloblastomas. *Am J Pathol*. 2000; 156(2):433–437. [PubMed: 10666372]
 35. Paraf F, Jothy S, Van Meir EG. Brain tumor-polyposis syndrome: two genetic diseases? *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 1997; 15 (7): 2744–2758. [PubMed: 9215849]
 36. Zurawel RH, Chiappa SA, Allen C, Raffel C. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. *Cancer Res*. 1998; 58(5):896–899. [PubMed: 9500446]
 37. Eberhart CG, Tihan T, Burger PC. Nuclear localization and mutation of beta-catenin in medulloblastomas. *J Neuropathol Exp Neurol*. 2000; 59(4):333–337. [PubMed: 10759189]
 38. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD. Medulloblastoma comprises four distinct molecular variants. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2010.10.1200/JCO.2009.27.4324
 39. Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, Pearson AD, Clifford SC. Committee UKCsCSGBT . beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumour Committee. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2005; 23(31):7951–7957.10.1200/JCO.2005.01.5479 [PubMed: 16258095]
 40. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2009; 27(10): 1627–1636.10.1200/JCO.2008.17.9432 [PubMed: 19255330]
 41. Eberhart CG, Kratz JE, Schuster A, Goldthwaite P, Cohen KJ, Perlman EJ, Burger PC. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. *Brain Pathol*. 2002; 12(1):36–44. [PubMed: 11770900]
 42. Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, McLendon RE. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children’s Oncology Group. *Arch Pathol Lab Med*. 2002; 126(5):540–544. [PubMed: 11958658]
 43. Kleihues P, Schäuble B, zur Hausen A, Estève J, Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. *Am J Pathol*. 1997; 150(1):1–13. [PubMed: 9006316]
 44. Frank AJ, Hernan R, Hollander A, Lindsey JC, Lusher ME, Fuller CE, Clifford SC, Gilbertson RJ. The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. *Brain Res Mol Brain Res*. 2004; 121(1–2):137–140.10.1016/j.molbrainres.2003.11.016 [PubMed: 14969745]
 45. Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, Bouffet E, Malkin D, Hawkins C. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations.

- Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(8):1345–1350.10.1200/JCO.2009.23.5952 [PubMed: 20142599]
46. Pfaff E, Remke M, Sturm D, Benner A, Witt H, Milde T, von Bueren AO, Wittmann A, Schöttler A, Jorch N, Graf N, Kulozik AE, Witt O, Scheurlen W, von Deimling A, Rutkowski S, Taylor MD, Tabori U, Lichter P, Korshunov A, Pfister SM. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2010; 28(35):5188–5196.10.1200/JCO.2010.31.1670 [PubMed: 21060032]
 47. Mendrzyk F, Korshunov A, Toedt G, Schwarz F, Korn B, Joos S, Hochhaus A, Schoch C, Lichter P, Radlwimmer B. Iso-chromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeats. *Genes Chromosomes Cancer*. 2006; 45(4):401–410.10.1002/gcc.20304 [PubMed: 16419060]
 48. Di Marcotullio L, Ferretti E, De Smaele E, Argenti B, Mincione C, Zazzeroni F, Gallo R, Masuelli L, Napolitano M, Maroder M, Modesti A, Giangaspero F, Screpanti I, Alesse E, Gulino A. REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma. *Proc Natl Acad Sci USA*. 2004; 101(29):10833–10838.10.1073/pnas.0400690101 [PubMed: 15249678]
 49. Briggs KJ, Corcoran-Schwartz IM, Zhang W, Harcke T, Devereux WL, Baylin SB, Eberhart CG, Watkins DN. Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma. *Genes Dev*. 2008; 22(6):770–785.10.1101/gad.1640908 [PubMed: 18347096]
 50. Waha A, Waha A, Koch A, Meyer-Puttlitz B, Weggen S, Sörensen N, Tonn JC, Albrecht S, Goodyer CG, Berthold F, Wiestler OD, Pietsch T. Epigenetic silencing of the HIC-1 gene in human medulloblastomas. *J Neuropathol Exp Neurol*. 2003; 62(11):1192–1201. [PubMed: 14656076]
 51. Rood BR, Zhang H, Weitman DM, Cogen PH. Hyper-methylation of HIC-1 and 17p allelic loss in medulloblastoma. *Cancer Res*. 2002; 62(13):3794–3797. [PubMed: 12097291]
 52. Lindsey JC, Anderton JA, Lusher ME, Clifford SC. Epigenetic events in medulloblastoma development. *Neurosurg Focus*. 2005; 19(5):E10. [PubMed: 16398460]
 53. Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P, Pietrosanti L, De Smaele E, Ferretti E, Miele E, Pelloni M, De Simone G, Pedone EM, Gallinari P, Giorgi A, Steinkühler C, Vitagliano L, Pedone C, Schinin ME, Screpanti I, Gulino A. Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. *Nature Cell Biology*. 2010; 12(2):132–142.10.1038/ncb2013
 54. Peters I, Rehmet K, Wilke N, Kuczyk MA, Hennenlotter J, Eilers T, Machtens S, Jonas U, Serth J. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. *Mol Cancer*. 2007; 6:49.10.1186/1476-4598-6-49 [PubMed: 17634119]
 55. Lindsey JC, Lusher ME, Anderton JA, Bailey S, Gilbertson RJ, Pearson ADJ, Ellison DW, Clifford SC. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. *Carcinogenesis*. 2004; 25(5):661–668.10.1093/carcin/bgh055 [PubMed: 14688019]
 56. Lusher ME, Lindsey JC, Latif F, Pearson ADJ, Ellison DW, Clifford SC. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. *Cancer Res*. 2002; 62(20):5906–5911. [PubMed: 12384556]
 57. Kongkham PN, Northcott PA, Ra YS, Nakahara Y, Mainprize TG, Croul SE, Smith CA, Taylor MD, Rutka JT. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. *Cancer Res*. 2008; 68(23):9945–9953.10.1158/0008-5472.CAN-08-2169 [PubMed: 19047176]
 58. Nakahara Y, Northcott PA, Li M, Kongkham PN, Smith C, Yan H, Croul S, Ra Y-S, Eberhart C, Huang A, Bigner D, Grajkowska W, Van Meter T, Rutka JT, Taylor MD. Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma. *Neoplasia*. 2010; 12(1):20–27. [PubMed: 20072650]
 59. Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, Brat DJ, Perry A, Eberhart CG. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. *Cancer Res*. 2004; 64(21):7787–7793.10.1158/0008-5472.CAN-04-1446 [PubMed: 15520184]

60. Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton BA, Russell TL, Ellenbogen RG, Bernstein ID, Beachy PA, Olson JM. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. *Cancer Res.* 2004; 64(21):7794–7800.10.1158/0008-5472.CAN-04-1813 [PubMed: 15520185]
61. Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, Esposito V, Galeone A, Navas L, Esposito S, Gargiulo S, Fattat S, Donofrio V, Cinalli G, Brunetti A, Vecchio LD, Northcott PA, Delattre O, Taylor MD, Iolascon A, Zollo M. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. *PLoS One.* 2009; 4(3):e4998.10.1371/journal.pone.0004998 [PubMed: 19308264]
62. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD, Yan H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. *Cancer Res.* 2004; 64(15):5048–5050.10.1158/0008-5472.CAN-04-1170 [PubMed: 15289301]
63. Inda MM, Mercapide J, Muñoz J, Coullin P, Danglot G, Tuñon T, Martínez-Peñuela JM, Rivera JM, Burgos JJ, Bernheim A, Castresana JS. PTEN and DMBT1 homozygous deletion and expression in medulloblastomas and supratentorial primitive neuroectodermal tumors. *Oncol Rep.* 2004; 12(6):1341–1347. [PubMed: 15547761]
64. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS-v, Caron HN, Cloos J, Mersi A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, Ellison D, Clifford SC, Versteeg R. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. *PLoS One.* 2008; 3(8):e3088.10.1371/journal.pone.0003088 [PubMed: 18769486]
65. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology.* 2006; 24(12):1924–1931.10.1200/JCO.2005.04.4974 [PubMed: 16567768]
66. Cho Y-J, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, Gilbertson RJ, Gajjar A, Delattre O, Kool M, Ligon K, Meyerson M, Mesirov JP, Pomeroy SL. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology.* 2010.10.1200/JCO.2010.28.5148
67. Chen TT, Mora EC, Mealey J. Cultivation of medulloblastoma cells derived from simian adenovirus SA7-induced hamster brain tumor. *Cancer Res.* 1975; 35(12):3566–3570. [PubMed: 172225]
68. Rapp F, Pauluzzi S, Waltz TA, Burdine JA, Matsen FA, Levy B. Induction of brain tumors in newborn hamsters by simian adenovirus SA7. *Cancer Res.* 1969; 29(6):1173–1178. [PubMed: 4307781]
69. Zu Rhein GM, Varakis JN. Perinatal induction of medulloblastomas in Syrian golden hamsters by a human polyoma virus (JC). *Natl Cancer Inst Monogr.* 1979; 51:205–208. [PubMed: 225669]
70. Nagashima K, Yasui K, Kimura J, Washizu M, Yamaguchi K, Mori W. Induction of brain tumors by a newly isolated JC virus (Tokyo-1 strain). *Am J Pathol.* 1984; 116(3):455–463. [PubMed: 6089567]
71. Zurawel RH, Allen C, Wechsler-Reya R, Scott MP, Raffel C. Evidence that haploinsufficiency of Ptc leads to medulloblastoma in mice. *Genes Chromosomes Cancer.* 2000; 28(1):77–81. [PubMed: 10738305]
72. Goodrich LV, Milenkovi L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. *Science.* 1997; 277(5329):1109–1113. [PubMed: 9262482]
73. Wetmore C, Eberhart DE, Curran T. The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. *Cancer Res.* 2000; 60(8):2239–2246. [PubMed: 10786690]
74. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, Beachy PA. Medulloblastoma growth inhibition by hedgehog

- pathway blockade. *Science*. 2002; 297(5586):1559–1561.10.1126/science.1073733 [PubMed: 12202832]
75. Oliver TG, Read TA, Kessler JD, Mehmeti A, Wells JF, Huynh TTT, Lin SM, Wechsler-Reya RJ. Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. *Development*. 2005; 132(10):2425–2439.10.1242/dev.01793 [PubMed: 15843415]
 76. Lee Y, Miller HL, Russell HR, Boyd K, Curran T, McKinnon PJ. Patched2 modulates tumorigenesis in patched1 heterozygous mice. *Cancer Res*. 2006; 66(14):6964–6971.10.1158/0008-5472.CAN-06-0505 [PubMed: 16849540]
 77. Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. *Cancer Res*. 2001; 61(2):513–516. [PubMed: 11212243]
 78. Romer J, Curran T. Targeting medulloblastoma: small-molecule inhibitors of the Sonic Hedgehog pathway as potential cancer therapeutics. *Cancer Res*. 2005; 65(12):4975–4978.10.1158/0008-5472.CAN-05-0481 [PubMed: 15958535]
 79. Pogoriler J, Millen K, Utset M, Du W. Loss of cyclin D1 impairs cerebellar development and suppresses medulloblastoma formation. *Development*. 2006; 133(19):3929–3937.10.1242/dev.02556 [PubMed: 16943274]
 80. Kimura H, Stephen D, Joyner A, Curran T. Gli1 is important for medulloblastoma formation in Ptc1+/- mice. *Oncogene*. 2005; 24(25):4026–4036.10.1038/sj.onc.1208567 [PubMed: 15806168]
 81. Hahn H, Wojnowski L, Zimmer AM, Hall J, Miller G, Zimmer A. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. *Nat Med*. 1998; 4(5):619–622. [PubMed: 9585239]
 82. Hahn H, Wojnowski L, Specht K, Kappler R, Calzada-Wack J, Potter D, Zimmer A, Müller U, Samson E, Quintanilla-Martinez L, Zimmer A. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. *J Biol Chem*. 2000; 275(37):28341–28344.10.1074/jbc.C000352200 [PubMed: 10884376]
 83. Mao J, Ligon KL, Rakhlin EY, Thayer SP, Bronson RT, Rowitch D, McMahon AP. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. *Cancer Res*. 2006; 66(20):10171–10178.10.1158/0008-5472.CAN-06-0657 [PubMed: 17047082]
 84. Hatton BA, Villavicencio EH, Tsuchiya KD, Pritchard JI, Ditzler S, Pullar B, Hansen S, Knoblauch SE, Lee D, Eberhart CG, Hallahan AR, Olson JM. The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. *Cancer Res*. 2008; 68(6):1768–1776.10.1158/0008-5472.CAN-07-5092 [PubMed: 18339857]
 85. Yang Z-J, Ellis T, Markant SL, Read T-A, Kessler JD, Bourbonlous M, Schüller U, Machold R, Fishell G, Rowitch DH, Wainwright BJ, Wechsler-Reya RJ. Medulloblastoma can be initiated by deletion of patched in lineage-restricted progenitors or stem cells. *Cancer Cell*. 2008; 14(2):135–145.10.1016/j.ccr.2008.07.003 [PubMed: 18691548]
 86. Schüller U, Heine VM, Mao J, Kho AT, Dillon AK, Han Y-G, Huillard E, Sun T, Ligon AH, Qian Y, Ma Q, Alvarez-Buylla A, McMahon AP, Rowitch DH, Ligon KL. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. *Cancer Cell*. 2008; 14(2):123–134.10.1016/j.ccr.2008.07.005 [PubMed: 18691547]
 87. Lee Y, Kawagoe R, Sasai K, Li Y, Russell HR, Curran T, McKinnon PJ. Loss of suppressor-of-fused function promotes tumorigenesis. *Oncogene*. 2007; 26(44):6442–6447.10.1038/sj.onc.1210467 [PubMed: 17452975]
 88. Gaiano N, Kohtz JD, Turnbull DH, Fishell G. A method for rapid gain-of-function studies in the mouse embryonic nervous system. *Nat Neurosci*. 1999; 2(9):812–819.10.1038/12186 [PubMed: 10461220]
 89. Weiner HL, Bakst R, Hurlbert MS, Ruggiero J, Ahn E, Lee WS, Stephen D, Zagzag D, Joyner AL, Turnbull DH. Induction of medulloblastomas in mice by sonic hedgehog, independent of Gli1. *Cancer Res*. 2002; 62(22):6385–6389. [PubMed: 12438220]
 90. Orsulic S. An RCAS-TVA-based approach to designer mouse models. *Mamm Genome*. 2002; 13(10):543–547.10.1007/s00335-002-4003-4 [PubMed: 12420130]

91. Holland EC, Varmus HE. Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. *Proc Natl Acad Sci USA*. 1998; 95(3):1218–1223. [PubMed: 9448312]
92. Binning MJ, Niazi T, Pedone CA, Lal B, Eberhart CG, Kim KJ, Laterra J, Fults DW. Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth. *Cancer Res*. 2008; 68(19):7838–7845.10.1158/0008-5472.CAN-08-1899 [PubMed: 18829539]
93. McCall TD, Pedone CA, Fults DW. Apoptosis suppression by somatic cell transfer of Bcl-2 promotes Sonic Hedgehog-dependent medulloblastoma formation in mice. *Cancer Res*. 2007; 67(11):5179–5185.10.1158/0008-5472.CAN-06-4177 [PubMed: 17545597]
94. Browd SR, Kenney AM, Gottfried ON, Yoon JW, Walterhouse D, Pedone CA, Fults DW. N-myc can substitute for insulin-like growth factor signaling in a mouse model of sonic hedgehog-induced medulloblastoma. *Cancer Res*. 2006; 66(5):2666–2672.10.1158/0008-5472.CAN-05-2198 [PubMed: 16510586]
95. Rao G, Pedone CA, Del Valle L, Reiss K, Holland EC, Fults DW. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. *Oncogene*. 2004; 23(36):6156–6162.10.1038/sj.onc.1207818 [PubMed: 15195141]
96. Rao G, Pedone CA, Coffin CM, Holland EC, Fults DW. c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice. *Neoplasia*. 2003; 5(3):198–204. NO_DOI. [PubMed: 12869303]
97. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. *Genes Dev*. 2008; 22(4):436–448.10.1101/gad.1627008 [PubMed: 18281460]
98. Li Y, Lal B, Kwon S, Fan X, Saldanha U, Reznik TE, Kuchner EB, Eberhart C, Laterra J, Abounader R. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. *Cancer Res*. 2005; 65(20):9355–9362.10.1158/0008-5472.CAN-05-1946 [PubMed: 16230398]
99. Li Y, Guessous F, Johnson EB, Eberhart CG, Li X-N, Shu Q, Fan S, Lal B, Laterra J, Schiff D, Abounader R. Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. *Lab Invest*. 2008; 88(2):98–111.10.1038/labinvest.3700702 [PubMed: 18059365]
100. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. *Genes Dev*. 2000; 14(8):994–1004. [PubMed: 10783170]
101. Shakhova O, Leung C, van Montfort E, Berns A, Marino S. Lack of Rb and p53 delays cerebellar development and predisposes to large cell anaplastic medulloblastoma through amplification of N-Myc and Ptch2. *Cancer Res*. 2006; 66(10):5190–5200.10.1158/0008-5472.CAN-05-3545 [PubMed: 16707443]
102. Zindy F, Nilsson LM, Nguyen L, Meunier C, Smeyne RJ, Rehg JE, Eberhart C, Sherr CJ, Roussel MF. Hemangiosarcomas, medulloblastomas, and other tumors in Ink4c/p53-null mice. *Cancer Res*. 2003; 63(17):5420–5427. [PubMed: 14500377]
103. Lee Y, McKinnon PJ. DNA ligase IV suppresses medulloblastoma formation. *Cancer Res*. 2002; 62(22):6395–6399. [PubMed: 12438222]
104. Yan CT, Kaushal D, Murphy M, Zhang Y, Datta A, Chen C, Monroe B, Mostoslavsky G, Coakley K, Gao Y, Mills KD, Fazeli AP, Tepsuporn S, Hall G, Mulligan R, Fox E, Bronson R, De Girolami U, Lee C, Alt FW. XRCC4 suppresses medulloblastomas with recurrent translocations in p53-deficient mice. *Proc Natl Acad Sci USA*. 2006; 103(19):7378–7383.10.1073/pnas.0601938103 [PubMed: 16670198]
105. Frappart P-O, Lee Y, Lamont J, McKinnon PJ. BRCA2 is required for neurogenesis and suppression of medulloblastoma. *EMBO J*. 2007; 26(11):2732–2742.10.1038/sj.emboj.7601703 [PubMed: 17476307]

106. Tong W-M, Ohgaki H, Huang H, Granier C, Kleihues P, Wang Z-Q. Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice. *Am J Pathol.* 2003; 162(1):343–352. [PubMed: 12507917]
107. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, Kranenburg TA, Hogg T, Poppleton H, Martin J, Finkelstein D, Pounds S, Weiss A, Patay Z, Scoggins M, Ogg R, Pei Y, Yang Z-J, Brun S, Lee Y, Zindy F, Lindsey JC, Taketo MM, Boop FA, Sanford RA, Gajjar A, Clifford SC, Roussel MF, McKinnon PJ, Gutmann DH, Ellison DW, Wechsler-Reya R, Gilbertson RJ. Subtypes of medulloblastoma have distinct developmental origins. *Nature.* 2010.10.1038/nature09587
108. Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan Q-W, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe X-N, Gilmer HCF, Collins R, Nagaoka M, Phillips JJ, Jenkins RB, Tihan T, Vandenberg SR, James CD, Tanaka K, Taylor MD, Weiss WA, Chesler L. Pleiotropic role for MYCN in medulloblastoma. *Genes Dev.* 2010; 24(10):1059–1072.10.1101/gad.1907510 [PubMed: 20478998]
109. Cooper MK, Porter JA, Young KE, Beachy PA. Teratogen-mediated inhibition of target tissue response to Shh signaling. *Science.* 1998; 280(5369):1603–1607. [PubMed: 9616123]
110. Incardona JP, Gaffield W, Kapur RP, Roelink H. The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction. *Development.* 1998; 125(18):3553–3562. [PubMed: 9716521]
111. Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, Scott MP, Beachy PA. Effects of oncogenic mutations in Smoothed and Patched can be reversed by cyclopamine. *Nature.* 2000; 406(6799):1005–1009.10.1038/35023008 [PubMed: 10984056]
112. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothed. *Genes Dev.* 2002; 16(21):2743–2748.10.1101/gad.1025302 [PubMed: 12414725]
113. Chen JK, Taipale J, Young KE, Maiti T, Beachy PA. Small molecule modulation of Smoothed activity. *Proc Natl Acad Sci USA.* 2002; 99(22):14071–14076.10.1073/pnas.182542899 [PubMed: 12391318]
114. Robarge KD, Brunton SA, Castanedo GM, Cui Y, Dina MS, Goldsmith R, Gould SE, Guichert O, Gunzner JL, Halladay J, Jia W, Khojasteh C, Koehler MFT, Kotkow K, La H, Lalonde RL, Lau K, Lee L, Marshall D, Marsters JC, Murray LJ, Qian C, Rubin LL, Salphati L, Stanley MS, Stibbard JHA, Sutherlin DP, Ubhayaker S, Wang S, Wong S, Xie M. GDC-0449-a potent inhibitor of the hedgehog pathway. *Bioorg Med Chem Lett.* 2009; 19(19):5576–5581.10.1016/j.bmcl.2009.08.049 [PubMed: 19716296]
115. Romer JT, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H, Connelly M, Stewart CF, Gould S, Rubin LL, Curran T. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. *Cancer Cell.* 2004; 6(3):229–240.10.1016/j.ccr.2004.08.019 [PubMed: 15380514]
116. Tremblay MR, Lescarbeau A, Grogan MJ, Tan E, Lin G, Austad BC, Yu L-C, Behnke ML, Nair SJ, Hagel M, White K, Conley J, Manna JD, Alvarez-Diez TM, Hoyt J, Woodward CN, Sydor JR, Pink M, MacDougall J, Campbell MJ, Cushing J, Ferguson J, Curtis MS, McGovern K, Read MA, Palombella VJ, Adams J, Castro AC. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). *J Med Chem.* 2009; 52(14):4400–4418.10.1021/jm900305z [PubMed: 19522463]
117. Pan S, Wu X, Jiang J, Gao W, Wan Y, Cheng D, Han D, Liu J, Englund NP, Wang Y, Peukert S, Miller-Moslin K, Yuan J, Guo R, Matsumoto M, Vattay A, Jiang Y, Tsao J, Sun F, Pferdekamper AC, Dodd S, Tuntland T, Maniara W, Kelleher JF, Y-m Y, Warmuth M, Williams J, Dorsch M. Discovery of NVP-LDE225, a potent and selective smoothed antagonist. *ACS Med Chem Lett.* 2010; 1(3):130–134.10.1021/ml1000307
118. Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JF, Peukert S, Pan S, Wu X, Maira S-M, Garcia-Echeverria C, Briggs KJ, Watkins DN, Yao Y-m, Lengauer C, Warmuth M, Sellers WR, Dorsch M. Interfering with resistance to smoothed antagonists by inhibition of the PI3K pathway in medulloblastoma. *Sci Transl Med.* 2010; 2(51):51ra70.10.1126/scitranslmed.3001599

119. Kimura H, Ng JMY, Curran T. Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. *Cancer Cell*. 2008; 13(3):249–260.10.1016/j.ccr.2008.01.027 [PubMed: 18328428]
120. Rudin CM, Hann CL, Lattera J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, Low JA. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. *N Engl J Med*. 2009; 361(12):1173–1178.10.1056/NEJMoa0902903 [PubMed: 19726761]
121. Yauch RL, Dijkgraaf GJP, Aliche B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ. Smoothed mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. *Science*. 2009; 326(5952):572–574.10.1126/science.1179386 [PubMed: 19726788]
122. Dijkgraaf GJP, Aliche B, Weinmann L, Januario T, West K, Modrusan Z, Burdick D, Goldsmith R, Robarge K, Sutherlin D, Scales SJ, Gould SE, Yauch RL, de Sauvage FJ. Small molecule inhibition of GDC-0449 refractory smoothed mutants and downstream mechanisms of drug resistance. *Cancer Res*. 2011; 71(2):435–444.10.1158/0008-5472.CAN-10-2876 [PubMed: 21123452]
123. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2011; 17(8):2502–2511.10.1158/1078-0432.CCR-10-2745 [PubMed: 21300762]
124. Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee Y-C, Peaceman D, Ozdemirli M, Rodriguez O, MacDonald TJ, Albanese C, Toretsky JA, Uren A. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. *J Clin Invest*. 2011; 121(1):148–160.10.1172/JCI42874 [PubMed: 21183792]
125. Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, Reya T, Liu JO, Epstein EH, Stevens DA, Beachy PA. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. *Cancer Cell*. 2010; 17(4):388–399.10.1016/j.ccr.2010.02.027 [PubMed: 20385363]
126. Heine VM, Priller M, Ling J, Rowitch DH, Schüller U. Dexamethasone destabilizes Nmyc to inhibit the growth of hedgehog-associated medulloblastoma. *Cancer Res*. 2010; 70(13):5220–5225.10.1158/0008-5472.CAN-10-0554 [PubMed: 20530674]
127. Spiller SE, Ravanpay AC, Hahn AW, Olson JM. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. *J Neurooncol*. 2006; 79(3):259–270.10.1007/s11060-006-9142-0 [PubMed: 16645722]
128. Ecke I, Petry F, Rosenberger A, Tauber S, Mönkemeyer S, Hess I, Dullin C, Kimmina S, Pirngruber J, Johnsen SA, Uhmman A, Nitzki F, Wojnowski L, Schulz-Schaeffer W, Witt O, Hahn H. Antitumor effects of a combined 5-aza-2'-deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. *Cancer Res*. 2009; 69(3):887–895.10.1158/0008-5472.CAN-08-0946 [PubMed: 19155313]
129. Ohshima-Hosoyama S, Hosoyama T, Nelon LD, Keller C. IGF-1 receptor inhibition by picropodophyllin in medulloblastoma. *Biochem Biophys Res Commun*. 2010; 399(4):727–732.10.1016/j.bbrc.2010.08.009 [PubMed: 20692232]
130. Coon V, Laukert T, Pedone CA, Lattera J, Kim KJ, Fuhs DW. Molecular therapy targeting Sonic hedgehog and hepatocyte growth factor signaling in a mouse model of medulloblastoma. *Mol Cancer Ther*. 2010; 9(9):2627–2636.10.1158/1535-7163.MCT-10-0486 [PubMed: 20807782]




Fig. 1. Utility of genetically engineered mouse models in the development of therapeutics. Knowledge of genetic abnormalities (mutations or pathway aberrations) and transcriptional signatures in human medulloblastoma and hypotheses regarding the cell of origin can be used to develop mouse models of the disease. Depicted are some of the current mouse models available and which human medulloblastoma subgroups they represent. Mouse models can be used to study tumor biology, and cells isolated from these models can be used for high-throughput or candidate screening to identify novel approaches to therapy. Mouse models can also be used to test the efficacy of these therapies in vivo. Subgroup-specific therapies can be translated back to the clinic to improve treatment strategies for patients

Table 1

Use of SHH-associated medulloblastoma models for testing of targeted therapy

GEM	Drug	Target	GEM study outcome	Status in human clinical trials
<i>Ptch</i> ^{+/−} ; <i>p53</i> ^{+/−} <i>Ptch</i> ^{+/−} ; <i>p53</i> ^{−/−} allografts	Cyclopamine	SMO	Tumor regression	Preclinical only
<i>Ptch</i> ^{+/−} ; <i>p53</i> ^{−/−}	HhAntag-691	SMO	Tumor inhibition, prolonged survival	Preclinical only
<i>Ptch</i> ^{+/−} ; <i>Hic1</i> ^{+/−} allograft	IPI-926	SMO	Tumor regression	Phase I
<i>Ptch</i> ^{+/−} <i>Ptch</i> ^{+/−} ; <i>p53</i> ^{−/−} <i>Ptch</i> ^{+/−} ; <i>Hic1</i> ^{+/−} allografts	NVP-LDE225	SMO	Tumor regression, regrowth	Phase I
<i>Ptch</i> ^{+/−} allograft	GDC-0449	SMO	Tumor regression	Phase II
<i>Ptch</i> ^{+/−} ; <i>p53</i> ^{−/−} allograft	Bis-amide compound 5	SMO	Tumor regression; regression of GDC-0449 resistant tumors	Preclinical
<i>Ptch</i> ^{+/−} ; <i>p53</i> ^{−/−} allograft	Arsenic trioxide	GLI	Tumor inhibition	Phase II completed
<i>Ptch</i> ^{+/−} ; <i>p53</i> ^{−/−} allograft	Itraconazole	SMO	Tumor inhibition	Phase I in children
<i>SmoA1</i>	Suberoylanilide hydroxamic acid	Histone deacetylase	Increased apoptosis	
<i>Ptch</i> ^{+/−}	Valproic acid	Histone deacetylase	Combined with 5-azaC	Phase II
<i>Ptch</i> ^{+/−}	5-azaC	DNA methylating agent	Prevented tumors, prolonged survival when combined with VPA	
	Picropodophyllin	IGF-1R	Not in vivo	Preclinical
<i>SmoA1</i>	Gamma-secretase inhibitors	NOTCH signaling	Not in vivo?	Phase II completed
<i>RCAS/tv-a SHH + HGF</i>	HGF neutralizing antibody L2G7	HGF	Prolonged survival	Preclinical